Mediwound Ltd

NASDAQ MDWD

Data sourced from

and

Download Data

Mediwound Ltd Revenue for the year ending December 31, 2023: USD 18.69 M

Mediwound Ltd Revenue is USD 18.69 M for the year ending December 31, 2023, a -29.48% change year over year. The revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Mediwound Ltd Revenue for the year ending December 31, 2022 was USD 26.50 M, a 11.50% change year over year.
Mediwound Ltd Revenue for the year ending December 31, 2021 was USD 23.76 M, a 9.19% change year over year.
Mediwound Ltd Revenue for the year ending December 31, 2020 was USD 21.76 M, a -31.54% change year over year.
Mediwound Ltd Revenue for the year ending December 31, 2019 was USD 31.79 M, a 834.70% change year over year.

NASDAQ: MDWD

Mediwound Ltd

CEO	Prof. Lior Rosenberg M.D.
IPO Date	March 20, 2014
Location	Israel
Headquarters	42 Hayarkon Street, Yavne, Israel, 8122745
Employees	100
Sector	Healthcare
Industry	Biotechnology

Description

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Key trends